-
Something wrong with this record ?
Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study
L. Karnisova, O. Hradsky, K. Blahova, F. Fencl, Z. Dolezel, T. Zaoral, J. Zieg,
Language English Country Germany
Document type Journal Article
NLK
ProQuest Central
from 1996-01-01 to 1 year ago
CINAHL Plus with Full Text (EBSCOhost)
from 2012-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 1997-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 1996-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 1996-01-01 to 1 year ago
Family Health Database (ProQuest)
from 1996-01-01 to 1 year ago
Public Health Database (ProQuest)
from 1996-01-01 to 1 year ago
- MeSH
- Complement Activation immunology MeSH
- Biomarkers blood MeSH
- Renal Dialysis statistics & numerical data MeSH
- Child MeSH
- Hemolytic-Uremic Syndrome complications immunology MeSH
- Infant MeSH
- Complement C3 analysis MeSH
- Kidney physiopathology MeSH
- Humans MeSH
- Child, Preschool MeSH
- Prognosis MeSH
- Diarrhea complications immunology MeSH
- Retrospective Studies MeSH
- Risk Factors MeSH
- ROC Curve MeSH
- Check Tag
- Child MeSH
- Infant MeSH
- Humans MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
Diarrhea-associated hemolytic uremic syndrome is characterized by hemolytic anemia, thrombocytopenia, and acute kidney injury secondary to enteric infection, typically Shiga toxin-producing Escherichia coli. Shiga toxin 2 is able to activate alternative complement pathways; therefore, the aim of the study was to analyze C3 as a predictor of clinical courses in patients with diarrhea-associated hemolytic uremic syndrome. We hypothesized that the patients with increased complement activation at admission suffered from a more severe course. We retrospectively analyzed data of 33 pediatric patients between 1999 and 2015 in the Czech Republic. We tested the association of a C3 concentration with biochemical parameters and the clinical data reflecting the severity of the disease. We found significant correlation between the initial C3 and the duration of renal replacement therapy (r = - 0.62, p = 0.0001) and the initial glomerular filtration rate (r = 0.36, p = 0.026). Patients with C3 < 0.825 g/L needed renal replacement therapy and also had significantly more renal complications (p = 0.015).Conclusion: Based on our study, decreased C3 concentrations can be used as one of the risk factors that can help predict the need for acute dialysis and a more severe course of disease in children with diarrhea-associated hemolytic uremic syndrome. What is Known: • Shiga toxin modulates the function of complement regulatory proteins and thus contributes to complement activation in patients with diarrhea-associated hemolytic uremic syndrome. • Risk factors that can predict the need for acute renal replacement therapy and poor outcome in patients with diarrhea-associated hemolytic uremic syndrome are mainly the combination of oligoanuria, dehydration, leukocytosis, high hematocrit > 23%, and neurological involvement. What is New: • A lowered concentration of C3 at the time of initial presentation of diarrhea-associated hemolytic uremic syndrome was associated with more severe renal failure and the need for renal replacement therapy along with the development of more extra renal complications. • Decreased C3 at admission can predict complicated course of diarrhea-associated hemolytic uremic syndrome.
Paediatric Clinic University Hospital Brno Medical Faculty of Masaryk University Brno Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19000352
- 003
- CZ-PrNML
- 005
- 20190118112819.0
- 007
- ta
- 008
- 190107s2018 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00431-018-3255-2 $2 doi
- 035 __
- $a (PubMed)30251107
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Karnisova, Lucia $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic. Lucia.Karnisova@fnmotol.cz.
- 245 10
- $a Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study / $c L. Karnisova, O. Hradsky, K. Blahova, F. Fencl, Z. Dolezel, T. Zaoral, J. Zieg,
- 520 9_
- $a Diarrhea-associated hemolytic uremic syndrome is characterized by hemolytic anemia, thrombocytopenia, and acute kidney injury secondary to enteric infection, typically Shiga toxin-producing Escherichia coli. Shiga toxin 2 is able to activate alternative complement pathways; therefore, the aim of the study was to analyze C3 as a predictor of clinical courses in patients with diarrhea-associated hemolytic uremic syndrome. We hypothesized that the patients with increased complement activation at admission suffered from a more severe course. We retrospectively analyzed data of 33 pediatric patients between 1999 and 2015 in the Czech Republic. We tested the association of a C3 concentration with biochemical parameters and the clinical data reflecting the severity of the disease. We found significant correlation between the initial C3 and the duration of renal replacement therapy (r = - 0.62, p = 0.0001) and the initial glomerular filtration rate (r = 0.36, p = 0.026). Patients with C3 < 0.825 g/L needed renal replacement therapy and also had significantly more renal complications (p = 0.015).Conclusion: Based on our study, decreased C3 concentrations can be used as one of the risk factors that can help predict the need for acute dialysis and a more severe course of disease in children with diarrhea-associated hemolytic uremic syndrome. What is Known: • Shiga toxin modulates the function of complement regulatory proteins and thus contributes to complement activation in patients with diarrhea-associated hemolytic uremic syndrome. • Risk factors that can predict the need for acute renal replacement therapy and poor outcome in patients with diarrhea-associated hemolytic uremic syndrome are mainly the combination of oligoanuria, dehydration, leukocytosis, high hematocrit > 23%, and neurological involvement. What is New: • A lowered concentration of C3 at the time of initial presentation of diarrhea-associated hemolytic uremic syndrome was associated with more severe renal failure and the need for renal replacement therapy along with the development of more extra renal complications. • Decreased C3 at admission can predict complicated course of diarrhea-associated hemolytic uremic syndrome.
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a aktivace komplementu $x imunologie $7 D003167
- 650 _2
- $a komplement C3 $x analýza $7 D003176
- 650 _2
- $a Česká republika $7 D018153
- 650 _2
- $a průjem $x komplikace $x imunologie $7 D003967
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a hemolyticko-uremický syndrom $x komplikace $x imunologie $7 D006463
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a ledviny $x patofyziologie $7 D007668
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a ROC křivka $7 D012372
- 650 _2
- $a dialýza ledvin $x statistika a číselné údaje $7 D006435
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a rizikové faktory $7 D012307
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hradsky, Ondrej $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Blahova, Kveta $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Fencl, Filip $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Dolezel, Zdenek $u Paediatric Clinic, University Hospital Brno, Medical Faculty of Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Zaoral, Tomas $u The Clinic of Paediatrics, Faculty of Medicine, University of Ostrava, University Hospital Ostrava, Ostrava, Czech Republic.
- 700 1_
- $a Zieg, Jakub $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic.
- 773 0_
- $w MED00009638 $t European journal of pediatrics $x 1432-1076 $g Roč. 177, č. 12 (2018), s. 1837-1844
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30251107 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20190118113033 $b ABA008
- 999 __
- $a ok $b bmc $g 1364459 $s 1038475
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 177 $c 12 $d 1837-1844 $e 20180924 $i 1432-1076 $m European journal of pediatrics $n Eur J Pediatr $x MED00009638
- LZP __
- $a Pubmed-20190107